



## Stereotaxis to Present at 29th Annual ROTH Conference

March 7, 2017

ST. LOUIS, March 07, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and Acting Chief Executive Officer, is scheduled to present at the 29th Annual ROTH Conference. The conference is taking place March 12-15, 2017 in Dana Point, CA.

Mr. Fischel will provide an overview of the Company's technology and business during his presentation on Wednesday, March 15, 2017 at 12:00 p.m. PT. In addition, he will be available to participate in one-on-one meetings with investors and other conference attendees. The Annual ROTH Conference is a premier conference designed to provide investors with the opportunity to gain insight into emerging growth companies. Over 4,000 attendees are expected at this year's conference.

"Re-engaging with capital markets is one of several key initiatives we are pursuing following my recent appointment as CEO," said David Fischel. "I am delighted that the ROTH Conference is our first opportunity to do so."

### **About Stereotaxis**

Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Over 100 issued patents support the Stereotaxis platform. The core components of Stereotaxis' systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit [www.stereotaxis.com](http://www.stereotaxis.com).

*This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to raise additional capital on a timely basis and on terms that are acceptable, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness, or to obtain additional financing, in either case on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from healthcare reform in the United States, including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.*

Company Contact:

David Fischel  
Chairman and Acting Chief Executive Officer  
314-678-6101

Martin C. Stammer  
Chief Financial Officer  
314-678-6155



Stereotaxis, Inc.